Ahead of print
Research paper
Published online: 2020-07-08
Submitted: 2020-04-15
Accepted: 2020-05-29
Get Citation

Validation of the Polish version of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)

Joanna Siuda, Magdalena Boczarska-Jedynak, Sławomir Budrewicz, Monika Figura, Urszula Fiszer, Agata Gajos, Agnieszka Gorzkowska, Ewa Koziorowska-Gawron, Dariusz Koziorowski, Anna Krygowska-Wajs, Monika Rudzińska-Bar, Jarosław Sławek, Xuehan Ren, Sheng Luo, Pablo Martinez-Martin, Glenn Stebbins, Christopher G. Goetz, Grzegorz Opala, Andrzej Bogucki, Jarosław Dulski, Piotr Janik, Magdalena Koszewicz, Marta Leńska-Mieciek, Małgorzata Michałowska, Marta Piaścik-Gromada, Katarzyna Potasz-Kulikowska, Marek Śmiłowski, Anna Wasielewska, Magdalena Wójcik-Pędziwiatr
DOI: 10.5603/PJNNS.a2020.0049
·
Pubmed: 32639019

paid access

Ahead of print
Research paper
Published online: 2020-07-08
Submitted: 2020-04-15
Accepted: 2020-05-29

Abstract

Background. In 2008, the Movement Disorders Society (MDS) published a new Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) as the official benchmark scale for Parkinson’s Disease (PD). We have translated and validated the Polish version of the MDS-UPDRS, explored its dimensionality, and compared it to the original English one. Methods. The MDS-UPDRS was translated into Polish by a team of Polish investigators led by JS and GO. The back-translation was completed by colleagues fluent in both languages (Polish and English) who were not involved in the original translation, and was reviewed by members of the MDS Rating Scales Programme. Then the translated version of the MDS-UPDRS underwent cognitive pretesting, and the translation was modified based on the results. The final translation was approved as the Official Working Document of the MDS-UPDRS Polish version, and was tested on 355 Polish PD patients recruited at movement disorders centres all over Poland (at Katowice, Gdańsk, Łódź, Warsaw, Wrocław, and Kraków). Confirmatory and explanatory factor analyses were applied to determine whether the factor structure of the English version could be confirmed in the Polish version. Results. The Polish version of the MDS-UPDRS showed satisfactory clinimetric properties. The internal consistency of the Polish version was satisfactory. In the confirmatory factor analysis, all four parts had greater than 0.90 comparative fit index (CFI) compared to the original English MDS-UPDRS. Explanatory factor analysis suggested that the Polish version differed from the English version only within an acceptable range. Conclusions and clinical implications. The Polish version of the MDS-UPDRS meets the requirements to be designated as the Official Polish Version of the MDS-UPDRS, and is available on the MDS web page. We strongly recommend using the MDS-UPDRS instead of the UPDRS for research purposes and in everyday clinical practice.

 

Abstract

Background. In 2008, the Movement Disorders Society (MDS) published a new Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) as the official benchmark scale for Parkinson’s Disease (PD). We have translated and validated the Polish version of the MDS-UPDRS, explored its dimensionality, and compared it to the original English one. Methods. The MDS-UPDRS was translated into Polish by a team of Polish investigators led by JS and GO. The back-translation was completed by colleagues fluent in both languages (Polish and English) who were not involved in the original translation, and was reviewed by members of the MDS Rating Scales Programme. Then the translated version of the MDS-UPDRS underwent cognitive pretesting, and the translation was modified based on the results. The final translation was approved as the Official Working Document of the MDS-UPDRS Polish version, and was tested on 355 Polish PD patients recruited at movement disorders centres all over Poland (at Katowice, Gdańsk, Łódź, Warsaw, Wrocław, and Kraków). Confirmatory and explanatory factor analyses were applied to determine whether the factor structure of the English version could be confirmed in the Polish version. Results. The Polish version of the MDS-UPDRS showed satisfactory clinimetric properties. The internal consistency of the Polish version was satisfactory. In the confirmatory factor analysis, all four parts had greater than 0.90 comparative fit index (CFI) compared to the original English MDS-UPDRS. Explanatory factor analysis suggested that the Polish version differed from the English version only within an acceptable range. Conclusions and clinical implications. The Polish version of the MDS-UPDRS meets the requirements to be designated as the Official Polish Version of the MDS-UPDRS, and is available on the MDS web page. We strongly recommend using the MDS-UPDRS instead of the UPDRS for research purposes and in everyday clinical practice.

 

Get Citation

Keywords

MDS-UPDRS, Parkinson’s Disease, rating scale, validation, translation

About this article
Title

Validation of the Polish version of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)

Journal

Neurologia i Neurochirurgia Polska

Issue

Ahead of print

Published online

2020-07-08

DOI

10.5603/PJNNS.a2020.0049

Pubmed

32639019

Keywords

MDS-UPDRS
Parkinson’s Disease
rating scale
validation
translation

Authors

Joanna Siuda
Magdalena Boczarska-Jedynak
Sławomir Budrewicz
Monika Figura
Urszula Fiszer
Agata Gajos
Agnieszka Gorzkowska
Ewa Koziorowska-Gawron
Dariusz Koziorowski
Anna Krygowska-Wajs
Monika Rudzińska-Bar
Jarosław Sławek
Xuehan Ren
Sheng Luo
Pablo Martinez-Martin
Glenn Stebbins
Christopher G. Goetz
Grzegorz Opala
Andrzej Bogucki
Jarosław Dulski
Piotr Janik
Magdalena Koszewicz
Marta Leńska-Mieciek
Małgorzata Michałowska
Marta Piaścik-Gromada
Katarzyna Potasz-Kulikowska
Marek Śmiłowski
Anna Wasielewska
Magdalena Wójcik-Pędziwiatr

References (17)
  1. Emamzadeh FN, Surguchov A. Parkinson's Disease: Biomarkers, Treatment, and Risk Factors. Front Neurosci. 2018; 12: 612.
  2. Barc K, Kuźma-Kozakiewicz M. Positron emission tomography neuroimaging in neurodegenerative diseases: Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Neurol Neurochir Pol. 2019; 53(2): 99–112.
  3. Malec-Litwinowicz M, Plewka A, Plewka D, et al. The relation between plasma α-synuclein level and clinical symptoms or signs of Parkinson's disease. Neurol Neurochir Pol. 2018; 52(2): 243–251.
  4. Fahn S, Elton RL, Members of, et al. Members of the UPDRS Develoment Committee. Unified Parkinson’s Disease rating scale. In:, , , , editors. Recent develoments in Parkinson’s disease, vol. 2. Florham Park, NJ: Macmillan Health Care Information; 1987. : 153–164.
  5. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008; 23(15): 2129–2170.
  6. Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol. 2013; 260(1): 228–236.
  7. Goetz CG, Stebbins GT, Wang Lu, et al. IPMDS-Sponsored Scale Translation Program: Process, Format, and Clinimetric Testing Plan for the MDS-UPDRS and UDysRS. Mov Disord Clin Pract. 2014; 1(2): 97–101.
  8. Fowler FJ. Improving Survey Questions: Design and Evaluation. Applied Social Research Methods Series: 38. Thousand Oaks: Sage. : 1995.
  9. Muthen LK. and Muthen BO. M plus Version 7 User's Guide. Los Angeles, CA: Muthen. : Muthen.
  10. Hatcher L. Step-by-step approach to using the SAS system for factor analysis and structural equation modeling. 1994. SAS Inst. , Cary, NC. ; 73.
  11. Brown TA. Confirmatory factor analysis for applied research. New York: Guilford SAGE Publications, Inc. : 2006.
  12. Browne M. An Overview of Analytic Rotation in Exploratory Factor Analysis. Multivariate Behavioral Research. 2010; 36(1): 111–150.
  13. Gorsuch RL. Factor analysis. Second edition. Hillsdale, NJ: Lawrence Erlbaum Associations, Inc. : 1983.
  14. Gallagher DA, Goetz CG, Stebbins G, et al. Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease. Mov Disord. 2012; 27(1): 79–83.
  15. Goetz CG, Liu Y, Stebbins GT, et al. Gender-, age- and race/ethnicity-based Differential Item Functioning (DIF) analysis of MDS-UPDRS. Mov Disord. 2016; 31(12): 1865–1873.
  16. Martínez-Martín P, Rodríguez-Blázquez C, Forjaz MJ, et al. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients. Eur J Neurol. 2014; 21(3): 519–524.
  17. Balash Y, Korczyn AD, Knaani J, et al. Quality-of-life perception by Parkinson's disease patients and caregivers. Acta Neurol Scand. 2017; 136(2): 151–154.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl